Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review.

Int J Environ Res Public Health · 2022 · PMC9739125 · PMID 36498053

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Conclusions Due to the heterogeneity of the results obtained in the present review, we cannot robustly demonstrate a relationship between elevated sclerostin serum levels and the development of CVD and/or cardiovascular mortality in the general population; however, there does appear to be a positive trend in specific populations.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.